We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Read MoreHide Full Article
Amgen (AMGN - Free Report) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.
Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood cancer that develops in the bone marrow.
Consolidation treatment is given to cancer patients after their cancer has disappeared following initial treatment. This therapy is given to kill any cancer cells that may be left in the body. The risk of B-ALL recurrence after initial treatment is relatively high, which makes the approval for consolidation treatment important.
The approval for consolidation treatment was based on data from the phase III E1910 study. Data from the study showed that Blincyto added to multiphase consolidation chemotherapy reduced the risk of death by 58%, showing superior overall survival versus chemotherapy alone.
So far this year, Amgen’s stock has risen 3.7% against the industry‘s 6.4% decline.
Image Source: Zacks Investment Research
The approval for consolidation treatment marks the third indication for Blincyto. It is already approved for treating CD19-positive B-ALL in adult and pediatric patients one month and older with MRD greater than or equal to 0.1% in first or second complete remission and those with relapsed or refractory disease.
Blincyto is a key contributor to Amgen’s top line and generated sales of $861 million in 2023, rising 48% year over year.
Amgen’s other BiTE therapy, which was recently approved in May, was Imdelltra (tarlatamab) for treating pre-treated advanced small cell lung cancer (ES-SCLC).
In the past 60 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share has increased from $4.56 to $4.71. During the same time frame, the consensus estimate for Ligand’s 2025 earnings per share has increased from $5.20 to $5.90. Year to date, shares of LGND have risen 12.1%.
Ligand beat estimates in each of the trailing four quarters, delivering an average surprise of 56.02%.
In the past 60 days, estimates for Twist Biosciences’ loss per share have narrowed from $3.17 to $3.08 for 2024 and from $2.81 to $2.64 for 2025. Year to date, shares of TWST have climbed 35.2%.
Twist Biosciences beat estimates in each of the trailing four quarters, delivering an average surprise of 9.36%.
In the past 60 days, the Zacks Consensus Estimate for Annovis’ loss per share has narrowed from $3.35 to $2.46 for 2024 and from $2.82 to $1.95 for 2025. Year to date, shares of ANVS have plunged 68.7%.
ANVS beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average negative earnings surprise of 1.39%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.
Image: Bigstock
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Amgen (AMGN - Free Report) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.
Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood cancer that develops in the bone marrow.
Consolidation treatment is given to cancer patients after their cancer has disappeared following initial treatment. This therapy is given to kill any cancer cells that may be left in the body. The risk of B-ALL recurrence after initial treatment is relatively high, which makes the approval for consolidation treatment important.
The approval for consolidation treatment was based on data from the phase III E1910 study. Data from the study showed that Blincyto added to multiphase consolidation chemotherapy reduced the risk of death by 58%, showing superior overall survival versus chemotherapy alone.
So far this year, Amgen’s stock has risen 3.7% against the industry‘s 6.4% decline.
Image Source: Zacks Investment Research
The approval for consolidation treatment marks the third indication for Blincyto. It is already approved for treating CD19-positive B-ALL in adult and pediatric patients one month and older with MRD greater than or equal to 0.1% in first or second complete remission and those with relapsed or refractory disease.
Blincyto is a key contributor to Amgen’s top line and generated sales of $861 million in 2023, rising 48% year over year.
Amgen’s other BiTE therapy, which was recently approved in May, was Imdelltra (tarlatamab) for treating pre-treated advanced small cell lung cancer (ES-SCLC).
Zacks Rank & Stocks to Consider
Amgen currently carries a Zacks Rank #3 (Hold).
Amgen Inc. Price and Consensus
Amgen Inc. price-consensus-chart | Amgen Inc. Quote
Some better-ranked stocks from the drug/biotech industry are Ligand Pharmaceuticals , Twist Bioscience (TWST - Free Report) and Annovis Bio (ANVS - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share has increased from $4.56 to $4.71. During the same time frame, the consensus estimate for Ligand’s 2025 earnings per share has increased from $5.20 to $5.90. Year to date, shares of LGND have risen 12.1%.
Ligand beat estimates in each of the trailing four quarters, delivering an average surprise of 56.02%.
In the past 60 days, estimates for Twist Biosciences’ loss per share have narrowed from $3.17 to $3.08 for 2024 and from $2.81 to $2.64 for 2025. Year to date, shares of TWST have climbed 35.2%.
Twist Biosciences beat estimates in each of the trailing four quarters, delivering an average surprise of 9.36%.
In the past 60 days, the Zacks Consensus Estimate for Annovis’ loss per share has narrowed from $3.35 to $2.46 for 2024 and from $2.82 to $1.95 for 2025. Year to date, shares of ANVS have plunged 68.7%.
ANVS beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average negative earnings surprise of 1.39%.